ATE234918T1 - Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen - Google Patents

Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen

Info

Publication number
ATE234918T1
ATE234918T1 AT96926042T AT96926042T ATE234918T1 AT E234918 T1 ATE234918 T1 AT E234918T1 AT 96926042 T AT96926042 T AT 96926042T AT 96926042 T AT96926042 T AT 96926042T AT E234918 T1 ATE234918 T1 AT E234918T1
Authority
AT
Austria
Prior art keywords
alpha
tnf
monoclonal antibodies
receptors
analogues
Prior art date
Application number
AT96926042T
Other languages
English (en)
Inventor
Serbec Vladka Curin
Annette Schuurbiers
Viktor Menart
Porekar Vladimira Gaderc
Anton Stalc
Petra Zunec
Janja Ocvirk
Borut Stabuc
Original Assignee
Lek Tovarna Farmacevtskih
Zd Republike Slovenije Za Tran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SI9500249A external-priority patent/SI9500249B/sl
Priority claimed from SI9600206A external-priority patent/SI9600206B/sl
Application filed by Lek Tovarna Farmacevtskih, Zd Republike Slovenije Za Tran filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of ATE234918T1 publication Critical patent/ATE234918T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT96926042T 1995-08-04 1996-07-31 Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen ATE234918T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI9500249A SI9500249B (sl) 1995-08-04 1995-08-04 Monoklonska protitelesa proti topnima TNF-alfa receptorjema p55 in p75 ter TNF-alfa in njegovim analogom
SI9600206A SI9600206B (sl) 1996-06-28 1996-06-28 Monoklonska protitelesa proti topnima TNF-alfa receptorjema p55 in p75 ter TNF-alfa in njegovim analogom
PCT/SI1996/000018 WO1997006251A1 (en) 1995-08-04 1996-07-31 MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-α RECEPTORS p55 and p75 AS WELL AS AGAINST TNF-α AND ITS ANALOGUES

Publications (1)

Publication Number Publication Date
ATE234918T1 true ATE234918T1 (de) 2003-04-15

Family

ID=26665256

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926042T ATE234918T1 (de) 1995-08-04 1996-07-31 Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen

Country Status (5)

Country Link
EP (1) EP0846169B1 (de)
AT (1) ATE234918T1 (de)
AU (1) AU703091B2 (de)
DE (1) DE69626829T2 (de)
WO (1) WO1997006251A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
WO2000020578A1 (en) * 1998-10-06 2000-04-13 The Walter And Eliza Hall Institute Of Medical Research A method of modulating cell survival and reagents useful for same
US6649352B1 (en) * 1999-01-29 2003-11-18 Center For Molecular Medicine And Immunology Method of evaluating myelosuppressive state
US7112409B2 (en) 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
WO2000056405A2 (en) * 1999-03-22 2000-09-28 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
SI21373A (sl) * 2002-11-22 2004-06-30 LEK farmacevtska družba d.d. Metoda za moduliranje biološke aktivnosti proteinov
EP2371390A3 (de) * 2004-10-08 2013-03-13 Domantis Limited Antagonisten und Verwendungsverfahren dafür
WO2007060411A1 (en) * 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
US10023628B2 (en) † 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
JP2647427B2 (ja) * 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
DE3823804A1 (de) * 1988-07-14 1990-01-18 Basf Ag Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
EP0589982B1 (de) * 1991-06-19 2001-01-17 Boehringer Ingelheim International GmbH Monoklonale antikörper gegen das humane tnf-bindende protein i (tnf-bp i)

Also Published As

Publication number Publication date
DE69626829T2 (de) 2004-03-18
EP0846169A1 (de) 1998-06-10
EP0846169B1 (de) 2003-03-19
WO1997006251A1 (en) 1997-02-20
AU6634596A (en) 1997-03-05
AU703091B2 (en) 1999-03-18
DE69626829D1 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE234918T1 (de) Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
UA40611C2 (uk) Імунокон'югат, спосіб його виготовлення, фармацевтична композиція
CA2256308A1 (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
ATE324441T1 (de) Htk-ligand
EP0821728A4 (de) Tie-2 liganden, herstellungsverfahren und verwendung
AU2001287000A1 (en) Modified polypeptides stabilized in a desired conformation and methods for producing same
CA2068222A1 (en) Monoclonal antibodies
DE69133242D1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
Delehanty et al. Identification of Important Residues in Metal− Chelate Recognition by Monoclonal Antibodies
JPH023697A (ja) 抗―ｒａｓ蛋白質抗体
WO1999002545A3 (en) Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
ATE275626T1 (de) Verfahren zur herstellung von rekombinanten menschlichen lh-rh rezeptor proteinen in spezifischen cho zellinien.
SG59954A1 (en) Improvements in granulocyte-macrophage colony- stimulating factor receptor and derivatives thereof
ATE164838T1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
EP0288520A1 (de) Verfahren zur verbesserung des "targeting" von antikörpern, antikörperteilen, hormonen und anderen "targeting"-substanzen sowie damit verwandte substanzen.
Spiegelberg et al. Human myeloma IgA half-molecules.
Baran et al. Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2.
WO2002012535B1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy
DE69611037D1 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
Isaacs et al. Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha 2-macroglobulin receptor recognition site.
IT1264083B1 (it) Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
Yoshitake et al. Production of monoclonal antibodies with specificity for different epitopes on the human epidermal growth factor molecule
Fowler et al. Amino acid sequence of beta-galactosidase. VI. Limited tryptic digestion of the citraconylated protein and sequences of tryptic peptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties